San Diego-dependent Viking Therapeutics marked itself as a serious competitor within the weight loss drug sector in February soon after revealing promising knowledge from the mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when given being a weekly injection and in March the company unv